OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of November 11, 2026, OVID stock price declined to $2.72 with 1,040,423 million shares trading.

OVID has a beta of 1.24, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.04 to the broad based SPY ETF.

OVID has a market cap of $513.35 million. This is considered a Small Cap stock.

Last quarter Ovid Therapeutics reported $0 in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-35,048 and missed earnings estimates by -$.02.

In the last 3 years, OVID traded as high as $4.10 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

OVID has outperformed the market in the last year with a price return of +101.5% while the SPY ETF gained +12.8%. OVID has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +3.8% and +20.4%, respectively, while the SPY returned -1.3% and -1.1%, respectively.

OVID support price is $2.63 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.